2026-04-17T03:12:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1786392025-11-20T15:05:50Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Fernández Sojo, Jesús author Azqueta, Carmen author Valdivia, Elena author Martorell, Lluis author Medina Boronat, Laura author Martínez Llonch, Nuria author Torrents, Silvia author Codinach, Margarita author Canals, Carme author Elorza, Izaskun author Parody, Rocío author Martino, Rodrigo author Trabazo, Maria author Díaz de Heredia, Cristina author Ferra, Christelle author Valcárcel, David author Linares, Mónica author Ancochea, Àgueda author García Rey, Enric author García Muñoz, Nadia author Medina, Laura author Castillo, Nerea author Carreras, Enric author Villa, Juliana author Querol Giner, Sergi author 2021-06-25T10:31:45Z 2021-06-25T10:31:45Z 2021-06-14 2021-06-25T10:07:54Z Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility was not well known. We compared 32 patients who underwent UD HSCT using cryopreserved peripheral blood stem cells (PBSC) during the COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period. Median neutrophil engraftment was 17.5 and 17.0 days with cryopreserved and fresh grafts, respectively. Non-significant delays were found in platelet recovery days (25.5 versus 19.0; P = 0.192) and full donor chimerism days (35.0 and 31.5; P = 0.872) using cryopreserved PBSC. The rate of acute graft-versus-host disease at 100 days was 41% (95% CI [21-55%]) in cryopreserved group versus 31% (95% CI [13-46%]) in fresh group (P = 0.380). One-hundred days progression-relapse free survival and overall survival did not differ significantly. During COVID-19 pandemic, six frozen UD donations were not transfused and logistical and clinical issues regarding cryopreservation procedure, packaging, and transporting appeared. In summary, UD HSCT with cryopreserved PBSC was safe during this challenging time. More efforts are needed to ensure that all frozen grafts are transplanted and cryopreservation requirements are harmonized. COVID-19 Cèl·lules mare COVID-19 Stem cells Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?